Top 10 articles for 2023 5 December 2023 Perhaps unsurprisingly the top stories during 2023 were related to the availability, or otherwise, of medications. The nationwide shortage of Ozempic hit the headlines at the start of 2023, and concerns still remain high for those struggling to access a regular supply. Several months later the potential withdrawal of Fiasp from the PBS understandingly sparked angst and distress in the community. These two issues were a major driving force behind the launch of our Spark Change platform. We have committed to fight for change on these issues, plus others. We urge you to add your voice on topics that concern you here. While Ozempic and Fiasp took out the top two spots for the most read articles on our website in 2023, the following eight articles were not far behind. Accessing your HbA1c results online through My Health Record Diabetes Australia welcomes cheaper, more convenient access to medicines Pain, numbness, burning? It could be peripheral neuropathy Recommended vaccinations for those living with type 2 diabetes Bionic pancreas approved by FDA Tube-free insulin pumps Pholcodine withdrawn: What you need to know about cough suppressants this winter Three commonly asked questions about exercise and diabetes
News 6 November 2024 Shape the future of diabetes research with your clinical research expertise and lived experience We are excited to announce an opportunity to contribute to the future of diabetes research in Australia. Diabetes Australia and... Continue Reading
News 4 November 2024 TGA warns fake Ozempic pens imported to Australia Counterfeit Ozempic-labelled pens are being sold in Australia. The Therapeutic Goods Administration (TGA) and the Australian Border Force (ABF) have... Continue Reading
Media releases 30 October 2024 Critical new diabetes support in the Melbourne CBD Vulnerable people living in Melbourne will have better access to diabetes education thanks to a new partnership between Diabetes Australia... Continue Reading